Prostate cancer — all decisions

The appeal was dismissed as the Veteran prematurely filed a Notice of Disagreement attempting to appeal a proposed reduction in rating that had not yet occurred.

The Board denied service connection for prostate cancer due to exposure to contaminated water at Marine Corps Base Camp Lejeune, finding no evidence linking the condition to in-service exposure.

The Board granted service connection for prostate cancer status post radical prostatectomy, erectile dysfunction, urinary incontinence, gastroesophageal reflux disease, and an acquired psychiatric disorder.

The Board denied a higher disability rating for PTSD and granted service connection for lumbosacral strain, while denying service connection for prostate cancer, erectile dysfunction, hypertension, and nuclear sclerosis and dry eye syndrome.

The Board remands the claims for service connection for hypertension and prostate cancer to correct duty-to-assist errors, including a formal finding on exposure to Agent Orange and obtaining additional medical records.

The Board denied the Veteran's claim for an earlier effective date for a 100 percent disability rating for prostate cancer with residuals of radiation cystitis status post bladder removal with urostomy, finding that the evidence did not support an earlier entitlement date.

The Board granted service connection for an acquired psychiatric disorder and a right foot disability, as secondary to service-connected disabilities. The appeals for service connection of prostate cancer, diabetes, GERD, and hypertension were dismissed due to the RO's subsequent grant of these conditions.

The Board remands the claims for service connection for hepatic cysts, kidney stones, and prostate cancer to correct a pre-decisional duty to assist error by the AOJ under the AMA.

The Board remands the claims for service connection for bilateral hearing loss, tinnitus, and prostate cancer due to incomplete records and inadequate medical opinions.

The Board remands the claim for service connection for prostate cancer to address toxic environmental exposure, including asbestos, high levels of chlorite, and PFAS.

The Board denied an earlier effective date for service connection of residuals of prostate cancer, finding that the August 10, 2022 effective date is appropriate under the PACT Act.

The Board denied the veteran's appeals for service connection due to untimely filings.

The Board denied the Veteran's claim for an earlier effective date than May 3, 2025, for prostate cancer.

The Veteran's service connection for discoid lupus was granted due to a nexus between his in-service exposure to Agent Orange and the current condition. The effective date of June 21, 2000, for prostate cancer residuals could not be earlier as it is the earliest possible date based on the recognition of Agent Orange exposure.

The Board granted service connection for prostate cancer with residuals, which is presumptively related to the Veteran's in-service herbicide exposure at U-Tapao base in Thailand during the Vietnam era.

The Board remands the claims for a rating reduction and increased rating for prostate cancer, as well as the TDIU claim, due to the need for additional development of evidence.

The Board denied an increased rating for prostate cancer and a compensable rating for myelodysplastic syndrome, but granted a separate rating for fatigue as a residual symptom of the service-connected myelodysplastic syndrome.

The Board remands the claims for service connection for prostate cancer, diabetes mellitus type II, and diabetic neuropathy of the upper and lower extremities due to a need for clarification regarding the Veteran's exposure to Agent Orange.

The Board remands the case to properly adjudicate the Veteran's HLR request for service connection for prostate cancer, as the AOJ erred by not considering the correct decision date.

The Board denied a compensable rating for erectile dysfunction and remanded issues related to earlier effective dates for the grants of service connection for prostate cancer, ED, and special monthly compensation.